UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
HLB to seek pre-NDA meeting with FDA for rivoceranib
HLB said it would request for a pre-New Drug Application (NDA) meeting with...
by Jeong Sae-im
|
2019-08-06 15:43
라인
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
Roche, MSD (Merck in the U.S.), and AstraZeneca achieved the most significa...
by Kim Yun-mi
|
2019-08-06 11:29
라인
Pharmicell submits investigational new drug application for prostate cancer treatment
Pharmicell said that it has filed an investigational new drug application t...
by Lee Han-soo
|
2019-08-05 17:59
라인
Sillajen’s trouble heralds fall of one of most prominent biotech firms
Shares of Sillajen continued to take a nosedive Monday after the biotech fi...
by Lee Han-soo
|
2019-08-05 16:55
라인
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
SillaJen said Pexa-Vec, an oncolytic viral drug, still had significant pote...
by Jeong Sae-im
|
2019-08-05 14:49
라인
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
With the likely suspension of SillaJen’s trial on its major anticancer pipe...
by Jeong Sae-im
|
2019-08-05 11:26
라인
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Local biotech shares went down altogether on Friday after SillaJen said it ...
by Jeong Sae-im
|
2019-08-02 15:45
라인
Eutilex pipelines are underrated: CEO
Eutilex CEO Kwon Byeong-se said he felt sorry for the recent fall of the co...
by Jeong Sae-im
|
2019-08-01 16:08
라인
Samsung BioLogics records Q2 operating loss
Samsung BioLogics logged an operating loss of 5.4 billion won ($13.1 millio...
by Lee Han-soo
|
2019-07-25 10:16
라인
Samsung Bioepis biosimilar sales in EU top $180 million in Q1
Samsung Bioepis’ sales in the European Union surpassed $180 million in the ...
by Lee Han-soo
|
2019-07-24 15:29
라인
Celltrion Healthcare joins Australia's pharma industry group
Celltrion Healthcare said that it has joined Australia's Generic and Bi...
by Lee Han-soo
|
2019-07-22 15:13
라인
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
The accounting fraud allegation involving Samsung BioLogics has been one of...
by Lee Han-soo
|
2019-07-19 18:16
라인
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
Samsung Bioepis said that the European Medicines Agency (EMA) has started e...
by Lee Han-soo
|
2019-07-19 17:01
라인
Celltrion targets Chinese biosimilar market through joint venture
Celltrion said it has established Vcell Healthcare Ltd., a joint venture wi...
by Lee Han-soo
|
2019-07-19 14:53
라인
Biopharmaceutical stocks face grim outlook in 2H
Biopharmaceutical stocks remain sluggish in the second half. Stock prices h...
by Jeong Sae-im
|
2019-07-17 14:11
라인
Celltrion starts P1 trial of Xolair biosimilar
Celltrion said Monday that it initiated the phase 1 clinical trial of CT-P3...
by Lee Han-soo
|
2019-07-15 17:45
라인
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
Colon cancer specialists questioned SillaJen’s allegation that the combinat...
by Jeong Sae-im, Kim Yun-mi
|
2019-07-12 15:13
라인
Court suspends decision on ministry’s order to revoke Invossa license
The Seoul Administrative Court on Thursday said it has temporarily suspende...
by Jeong Sae-im
|
2019-07-12 13:11
라인
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
The prosecution raided two securities firms that managed the initial public...
by Jeong Sae-im
|
2019-07-11 16:39
라인
NKMax America seeks NASDAQ listing
“Seeking NASDAQ listing as soon as possible, we will show the excellent eff...
by Jeong Sae-im
|
2019-07-11 12:41
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top